NMDA receptor antagonists in pain therapy;NMDA-rezeptorantagonisten in der schmerztherapie

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 33, Issue 8, 1998, Pages 475-483

  Weber, Carla ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Central sensitization; Ketamine; Neuropathic pain; NMDA receptor antagonists; Opioid tolerance

Indexed keywords

AMANTADINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ALLODYNIA; ANALGESIA; ANESTHESIA INDUCTION; MAINTENANCE THERAPY; PARKINSON DISEASE; REVIEW; SENSITIZATION;

EID: 0031852890     PISSN: 09392661     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994794     Document Type: Review

References (110)

1. Andersen OK, Felsby S, Nicolaisen L, Bjerring P, Jensen TS, Arendt-Nielsen L: The effect of ketamine on stimulation of primary and secondary hyperalgesic areas induced by capsaicin - a double-blind, placebo-controlled, human experimental study. Pain 1996;66:51-62
2. Arendt-Nielsen L, Petersen-Felix S, Fischer M, Bak P, Bjerring P, Zbinden AM: The effect of N-Methyl-D-aspartate antagonist (Ketamine) on single and repeated nociceptive stimuli: a placebo-controlled experimental human study. Anesth. Analg. 1995;81:63-68
3. Arńer S, Meyerson BA: Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988;33:11-23
4. Baber NG, Dourish CT, Hill DR: The role of CCK, caerulein, and CCK antagonists in nociception. Pain 1989;39:307-328
5. Backonja M, Arndt G, Gombar KA, Check B, Zimmermann M: Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. Pain 1994;56:51-57
6. Ben-Eliyahu S, Marek P, Vaccarino AL, Mogil JS, Sternberg WF, Liebeskind JC: The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. Brain Res. 1992;575:304-308
7. Bennett GJ, Xie Y-K: A peripheral mononeuropathy in the rat, that produce disorders of pain sensation like those seen in man. Pain 1988;33:87-107
8. Bennet GJ: In: Textbook of Pain. Wall PD, Melzack R (Hrsg.) Third edition 1994; Churchill Livingstone
9. Chapman V, Dicksenson AH: The combination of NMDA antagonism and morphine produce profound antinociception in the rat dorsal horn. Brain Res. 1992;573:321-323
10. Chen H-S, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA: Open channel block of NMDA responses by memantine: Therapeutic advantage against NMDA receptormediated neurotoxicity. J. Neurosci. 1992;12:4427-4436
11. Coderre TJ, Vaccarino AL, Melzack R: Central nervous system plasticity in the tonic pain response to subcutaneous formalin injection. Brain Res. 1990;535:155-158
12. Coderre TJ, Melzack R: The role of NMDA-Receptor-operated calcium channels in persistent nociception after formalininduced tissue injury. J. Neurosci. 1992;12:3671-3675
13. Coderre TJ, Katz L, Vaccarino L, Melzack R: Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993;52:259-285
14. Davar G, Hama A, Deykin A, Vos B, Maciewicz R: MK-801 blocks the development of thermal hyperalgesia in a rat model of experimental painful neuropathy. Brain Res. 1991;553:327-330
15. Davies SN, Lodge D: Evidence for involvement of N-methylaspartate receptors in "wind up" of class 2 neurones in the dorsal horn of the rat. Brain Res. 1987;424:402-406
16. Dickenson AH, Sullivan AF: Electrophysiological studies on the effects of intrathecal morphine on nociceptive neurons in the rat dorsal horn. Pain 1986;24:211-222
17. Dickenson AH, Sullivan AF: Subcutaneous formalin-induced activity of dorsal horn neurones in the rat: differential response to an intrathecal opiate administered pre or post formalin. Pain 1987;30:349-360
18. Dickenson AH, Sullivan AF: Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology 1987;26:1235-1238
19. Dickenson AH, Aydar E: Antagonism at the glycine site of the NMDA receptor reduces spinal nociception in the rat. Neurosci. Lett. 1991;121:263-266
20. Dickenson AH: NMDA receptor antagonists as analgesics. In: Pharmacological approaches to the treatment of chronic pain: new concepts and critical issues. Progress in pain research and management. Fields LF, Liebeskind JC (Hrsg.). IASP Press, Seattle 1994;1:173-187
21. Dickenson AH: Neurophysiology of opioid poorly responsive pain. Cancer Surv.. 1994;21:5-16
22. Dickenson AH: Spinal cord pharmacology of pain. Br. J. Anaesth. 1995;75:193-200
23. Dickenson AH: Central acute pain mechanisms. Ann. Med. 1995;27:223-227
24. Dubner R: Hyperalgesia and expanded receptive fields. Pain 1992;48:3-4
25. Eide PK, Jorum E, Stubhaug A, Bremnes J, Breivik H: Relief of post-herpetic neuralgia with the N-methyl-D-aspartate receptor antagonist ketamine: a double blind, cross-over comparison with morphine and placebo. Pain 1994;58:347-354
26. Eide PK, Stubhaug A, Oye I, Breivik H: Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain 1995;61:221-228
27. Eisenberg E, Vos BP, Strassman AM: The NMDA antagonist Memantine blocks pain behavior in a rat model of formalininduced facial pain. Pain 1993;54:301-307
28. Eisenberg E, LaCross S, Strassman AM: The effect of the clinically tested NMDA receptor antagonist memantine on carrageenan-induced thermal hyperalgesia in rats. Eur. J. Pharmacol. 1994;255:123-129
29. Elliott K, Minami N, Kolesnikov YA, Pasternak GW, Inturrisi CE: The NMDA receptor antagonists, LY 274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain 1994;56:69-75
30. Elliott K, Hynansky A, Inturrisi CE: Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain 1994;59:361-368
31. Elliott K, Kest B, Man A, Kao B, Inturrisi CE: N-Methyl-D-aspartate (NMDA) receptors, Mu and Kappa Opioid tolerance, and perspectives on new analgesic drug development. Neuropsychopharmacology 1995;13:347-356
32. Engelhardt W: Aufwachverhalten und psychomimetische Reaktionen nach S-(+)-Ketamin. Anaesthesist 1997;46 Suppl. 1:S 38-S42
33. Felsby S, Nielsen J, Arendt-Nielson L, Jensen TS: NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Pain 1995;64:283-291
34. Garthwaite J: Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci. 1991;14:60-67
35. Göbel H, Stolze H, Dworschak M, Heinze A: Der N-Methyl-D-aspartat-(NMDA)-antagonist Amantadinsulphat in der Prophylaxe der Migräne - Erste Erfahrungen. Schmerz 1995;9 Suppl. 1:S 46
36. Gordh T: Intervention with spinal NMDA, Adenosine, and NO Systems for Pain Modulation. Ann. Med. 1995;27:229-234
37. Haley JE, Sullivan AF, Dickenson AH: Evidence for spinal N-Methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat. Brain Res. 1990;518:218-226
38. Hao J-X, Xu X-J: Treatment of a chronic allodynia-like response in spinally injured rats: effects of systemically administered excitatory amino acid receptor antagonists. Pain 1996;66:279-285
39. Herbert MK, Ruppert U, Söllmann C, Sonnek G, Sonnek M: Pain, allodynia and neurogenic vasodilatation due to noxious heat or capsaicin are not reduced by the NMDA receptor antagonist memantine in healthy volunteers. Anesthesiology 1996;85: Suppl. A797
40. Herbert MK, Ruppert U, Söllmann C, Sonnek G, Sonnek M: Effect of the NMDA receptor antagonist Memantine in a non psychotomimetic dose on experimentally evoked pain in man. Anesth. Analg. 1997;84:S303
41. Herman BH, Vocci F, Bridge P: The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Neuropsychopharmacology 1995;13:269-293
42. Herrero JF, Headley PM, Parsons GG: Memantine selectively depresses NMDA receptor-mediated responses of rat spinal neurones in vivo. Neurosci. Lett. 1994;165:37-40
43. Hoheisel U, Sander S, Mense S: Blockade of nitric oxide synthase differentially influences background activity and electrical excitability in rat dorsal horn neurones. Neurosci. Lett. 1995;188:143-146
44. Hwang JH, Yaksh TL: The effect of spinal GABA receptor agonists on tactile allodynia in a surgically-induced neuropathic pain model in the rat. Pain 1997;70:15-22
45. Illkaer S, Petersen KL, Brennum J, Wernberg M, Dahl JB: Effect of systemic N-methyl-D-aspartate receptor antagonist (ketamine) on primary and secondary hyperalgesia in humans. Br. J. Anaesth. 1996;76:829-834
46. Jänig W: Biologie und Pathobiologie der Schmerzmechanismen. In: Lehrbuch der Schmerztherapie. Zenz M, Jurna I (Hrsg.) 1993; Wiss. Verl.-Ges.: Stuttgart
47. Kleinböhl D, Hölzl R, Möltner A, Osswald PM, Rommel C: Sensitization and adaptation to tonic heat stimulation in chronic pain patients. Abstracts 7th World Congress on Pain. Paris, France. IASP-Publications, Seattle 1993;Abs:1014
48. Kleinböhl D: Psychophysikalische Korrelate von Anpassungsprozessen bei lang dauernden Schmerzreizen bei Gesunden und chronischen Schmerzpatienten. Shaker-Verlag, Aachen 1996
49. Koltzenburg M, Torebjörk HE, Wahren LK: Nociceptor modulated central sensitization causes mechanical hyperalgesia in acute chemogenic and chronic neuropathic pain. Brain 1994; 117:579-591
50. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Pharmacol. 1989;166:589-590
51. Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P: Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA receptor-gated ion channel: a human postmortem brain study. Eur. J. Pharmacol. 1991;206:297-300
52. Kornhuber J. Schoppmeyer K, Riederer P: Affinity of 1-aminoadamantanes for the σ binding site in post-mortem human frontal cortex. Neurosci. Lett. 1993;163:129-131
53. Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P: Therapeutic brain concentrations of the NMDA receptor antagonist amantadine. Neuropharmacology 1995;34:713-721
54. Kress HG: Wirkmechanismen von Ketamin. Anaesthesist 1997;46Suppl.1:S8-S19
55. Kristensen JD, Svensson B, Gordh T Jr.: The NMDA-receptor antagonist CPP abolishes neurogenic "wind-up" pain after intrathecal administration in humans. Pain 1992;51:249-253
56. LaMotte RH: Can the sensitization of nociceptors account for hyperalgesia after skin injury? Hum. Neurobiol. 1984;3:7-52
57. LaMotte RH, Shain CN, Simone DA, Tsai E-FP: Neurogenic hyperalgesia: Psychophysiological studies of underlying mechanisms. J. Neurophysiol. 1991;66:190-211
58. Luczak J, Dickenson AH, Kotlinska-Lemieszek A: The role of Ketamine, an NMDA receptor antagonist, in the management of pain. Progr. Palliat Care 1995;3:127-134
59. MacDermott AB, Mayer ML, Westbrook GL, Smith SJ, Barker JL: NMDA-receptor activation increases cytoplasmatic calcium concentration in cultured spinal cord neurones. Nature 1986;321:519-522
60. Malmberg AB, Yash TL: Spinal nitric oxide synthesis inhibition blocks NMDA-induced thermal hyperalgesia and produces antinociception in the formalin test in rats. Pain 1993;54:291-300
61. Manning BH, Mao J, Frenk H. Price DD, Mayer DJ: Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxonereversible attenuation of morphine tolerance. Pain 1996; 67:79-88
62. Mao J, Price DD, Mayer DJ, Lu J, Hayes RL: Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy. Brain Res. 1992;576:254-262
63. Mao J, Price DD, Mayer DJ: Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J. Neurosci. 1994;14:2301-2312
64. Maurset A, Skoglund LA, Hustveit O, Oye I: Comparison of ketamine and pethidine in experimental and postoperative pain. Pain 1989;36:37-41
65. Max MB, Byas-Smith MG, Gracely RH, Bennett GJ: Intravenous infusion of the NMDA antagonist ketamine in chronic posttraumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. Clinical Neuropharmacology 1995;18: 360-368
66. Meldrum BS: Neuroprotection by NMDA and non-NMDA glutamate antagonists. In: Direct and allosteric control of glutamate receptors. Palfreyman MG, Reynolds D (Hrsg.) Boca Raton, CRP Press 1994;pp:127-138
67. Mendell LM, Wall PD: Responses of single dorsal cord cells to peripheral cutaneous unmyelinated fibres. Nature 1965;206: 97-99
68. Mense S: Nociception from skeletal muscle in relation to clinical muscle pain. Pain 1993;54:241-289
69. Mense S: Pathophysiologic basis of muscle pain syndromes. An update. Physical medicine and rehabilitation clinics of North America. 1997;8:23-53
70. Mercadante S, Lodi F, Sapio M, Calligara M, Serretta R: Long-term Ketamine subcutaneous infusion in neuropathic cancer pain. J. Pain Symptom Manage 1995;10:564-568
71. Mercadante S: Ketarnine in cancer pain: an update. Palliat. Med. 1996;10:225-230
72. Meßlinger K: Was ist ein Nozizeptor? Anästhesist 1997;46: 142-153
73. Neugebauer V, Kornhuber J, Lücke T, Schaible H-G: The clinically available NMDA receptor antagonist memantine is antinoceptive on rat spinal neurones. Neuroreport 1993;4: 1259-1262
74. Nowak L, Bregestovski P, Ascher P: Magnesium gates glutamate-activated channels in mouse central neurones. Nature 1984;307:462-465
75. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA: NMDA Antagonist Neurotoxicity: Mechanism and Prevention. Science 1991;254:1515-1518
76. Olney JW, Farber NB: NMDA Antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 1995;13: 335-345
77. Palfreyman MG: Glutamate receptors and their regulators: an overview. In: Direct and allosteric control of glutamate receptors. Palfreyman MG, Reynolds D (Hrsg.) Boca Raton, CRP Press 1994:pp 1-19
78. Park MK, Max MB, Robinovitz E, Gracely RH, Bennett GJ: Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects. Pain 1995;63:163-172
79. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D: Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyl-adamantan). Neuropsychopharmacology 1993;32:1337-1350
80. Pasternak GW, Kolesnikov YA, Babey A-M: Perspectives on the N-Methyl-D-aspartate/Nitric oxide cascade and opioid tolerance. Neuropsychopharmacology 1995;13:309-313
81. PerssonJ, Axelson G, Hallin RG, Gustafsson LL: Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization. Pain 1995;60:217-222
82. Pfenninger E, Himmelseher S: Neuroprotektion durch Ketamin auf zellulärer Ebene. Anaesthesist 1997;46 Suppl. 1:S 47-S 54
83. Popik P, Skolnick P: The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol. Biochem. Behav. 1996;53:791-797
84. Price D, Hu JW, Dubner R, Gracely RH: Peripheral suppression of first pain and central summation of second pain evoked by noxious heat pulses. Pain 1997;3:57-68
85. Price DD, Bennett GJ, Rafii A: Psychophysical observations on patients with neuropathic pain relieved by a sympathic block. Pain 1989;36:273-288
86. Price DD, Long S, Huitt C: Sensory testing of pathophysiological mechanisms of pain in patients with reflex sympathetic dystrophy. Pain 1992;49:163-173
87. Price DD, Mao J, Frenk H, Mayer DJ: N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man. Pain 1994;59: 165-174
88. Raigorodsky G, Urea G: Intrathecal NMDA activates both nociceptive and antinociceptive systems. Brain Res. 1987;422:158-162
89. Ren K: Wind-up and the NMDA receptor: from animal studies to humans. Pain 1994;59:157-158
90. Seltzer Z, Dubner R, Shir Y: A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990;43:205-218
91. Sher GD, Mitchell D: N-methyl-D-aspartate receptors mediate responses of rat dorsal horn neurones to hindlimb ischemia. Brain Res. 1990;522:55-62
92. Simone DA, Baumann TK, LaMotte RH: Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicin. Pain 1989;38:99-107
93. Simone DA, Sorkin LS, OH U, ChungJM, Owens C, LaMotte RH, Willis WD: Neurogenic hyperalgesia: central neural correlates in responses of spinothalamic tract neurons. J. Neurophysiol. 1991;66:228-246
94. Thalhammer JG, LaMotte RH: Spatial properties of nociceptor sensitization following heat injury of the skin. Brain Res. 1982;231:257-265
95. Treede R-D, Meyer RA, Raja SN, Campbell JN: Peripheral and central mechanisms of cutaneous hyperalgesia. Prog. Neurobiol. 1992;38:397-421
96. Trujillo KA, Akil H: Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991;251:85-87
97. Trujillo KA: Effects of noncompetitive NMDA receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacology 1995;13:301-307
98. Waldvogel HH: Analgetika, Antinozizeptiva. Adjuvantien. Handbuch für die Schmerzpraxis. Springer. 1996
99. Warncke T, Stubhaug A, Jorum E: Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burninduced secondary hyperalgesia in man: a double-blind, crossover comparison with morphine and placebo. Pain 1997;72: 99-106
100. Wiedemann B: Ketamin zur Therapie chronischer Schmerzen. Metaanalyse. Schmerz 1997;11:276-281
101. Wiertelak EP, Maier SF, Watkins LR: Cholecystokinin antianalgesia: safety cues abolish morphine analgesia. Science 1992; 256:830-833
102. Woolf CJ, King AE: Physiology and morphology of multireceptive neurons with C-afferent fiber inputs in the deep dorsal horn of the rat lumbar spinal cord. J. Neurophysiol. 1987;58:460-479
103. Woolf CJ, Thompson WN: The induction and maintenance of central sensitization is dependant on NMDA receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991;44:293-299
104. Xu X-J, Hao J-X, Aldskogius H, Wiesenfeld-Hallin Z: Chronic pain-related syndrome in rats after ischemic spinal cord lesion: a possible animal model for pain in patients with spinal cord injury. Pain 1992;48:279-290
105. Xu X-J, Puke MJC, Verge VMK, Wiesenfeld-Hallin Z, Hughes J, Hökfelt T: Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain in the rat. Neurosci. Lett. 1993; 152:129-132
106. Yamamoto T, Yaksh TL: Spinal pharmacology of thermal hyperesthesia induced by constriction of sciatic nerve. Excitatory aminoacid antagonists. Pain 1992;49:121-128
107. Yamamoto T, Yaksh TL: Studies on the spinal interaction of morphine and the NMDA antagonist MK-801 on the hyperesthesia observed in a rat model of sciatic mononeuropathy. Neurosci Lett. 1992;135:67-70
108. Yaksh TL, Malmberg AB: Interaction of spinal modulatory receptor systems. In: Progress in pain research and management. Fields HL, Liebeskind JC (Hrsg.) IASP Press, Seattle 1994;Vol 1:151-171
109. Yaksh TL, Malmberg AG: Central pharmacology of nociceptive transmission. In: Textbook of Pain. Wall PD, Melzack R (Hrsg.): Churchill Livingstone 3. Aufl. 1994:165-200
110. Yang CY, Wong CS, Chang JY, Ho ST: Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can. J. Anaesth. 1996;43:379-383